Cardioprotection During Cancer Treatment: What the Evidence Supports Now
Where baseline risk stratification, blood-pressure control, statins, neurohormonal therapy, and dose planning fit into protecting the heart before, during, and after cardiotoxic cancer therapy.
Cardioprotection is less a drug decision than a sequence: stratify before the first dose, control what is modifiable during treatment, and surveil on an interval set by exposure rather than by convenience.
Stratify before the first dose
Baseline assessment establishes ejection fraction and strain, blood pressure, lipids, glycaemia, renal function, and prior cardiovascular disease, and records the planned cumulative anthracycline dose and radiation field. Risk category then determines both the imaging interval and the threshold at which you act.
A baseline recorded after therapy has started is not a baseline. This is the step most often lost when treatment begins urgently.
What to control during treatment
Blood pressure control, statin therapy where indicated by overall cardiovascular risk, glycaemic and weight management addressed within the survivorship context, activity maintained rather than paused, and tobacco cessation. These are unglamorous and they carry more absolute benefit across a survivor population than any single cardioprotective agent.
Where anthracycline exposure is high, discuss dose fractionation, liposomal formulation, or dexrazoxane with the treating oncologist rather than assuming the plan is fixed.
Acting on a measured decline
For a meaningful decline in ejection fraction or a relative strain decline beyond the accepted threshold, guideline-directed neurohormonal therapy with an ACE inhibitor or angiotensin receptor blocker and a beta blocker is the standard response, with cardio-oncology involvement and a documented decision about continuing, holding, or modifying the cancer therapy.
Universal prophylaxis in unselected patients has not shown consistent benefit. Reserve it for high-risk profiles decided jointly with cardio-oncology.
Hand-off and ownership
Cardioprotection fails at the seams. Record who owns the next imaging study, who titrates the antihypertensive, and who reviews lipids, then put that ownership somewhere the survivor can carry between oncology, cardio-oncology, and primary care.
Frequently asked questions
- Should all patients receiving anthracyclines get prophylactic cardioprotective drugs?
- No. Evidence supports risk-stratified use in high-risk patients and treatment of measured decline, rather than universal prophylaxis in unselected patients.
- What is the most important cardioprotective step during cancer treatment?
- Establishing a true pre-treatment baseline and controlling blood pressure throughout, since uncontrolled hypertension amplifies the effect of every cardiotoxic exposure.